SLC5A2 and atrial fibrillation: Future research should focus on direct head-to-head trials, exploring mechanisms behind dapagliflozin's superior effect on atrial fibrillation, and conducting long-term studies to evaluate the sustained benefits and potential side effects of these SGLT2 inhibitors.